San Diego, CA (November 11, 2019) – Latitude Pharmaceuticals Inc. specializes in the formulation development and GLP Tox Toxicology Dose Escalation for the pharma and biotech industries. The company recently announced the notice of allowance they got from the United States Patent and Trademark Office that covers Stable Aqueous Vancomycin Formulations.

A Patent Examiner of USPTO has determined that the Vancomycin Formulation from Latitude named Intra-V is entitled to a patent under the United States Patent Law. As compared to other vancomycin products, Intra-V has a couple of benefits that are being currently developed and marketed. The first advantage is that it is a ready-to-use liquid format, while the other is a very safe profile. The reason is that intra-V does not encompass any unapproved, probably harmful or new ingredients. This is because of the experience of this as an Injectable Drug Depot.

Further, Intra-V also has the possibility to demonstrate bioequivalence to the vancomycin products that are already in use. Further, Latitude Pharma with experience in Drug Compound Stability Profile has made this formulation to have a very short development path to turn out to be the vancomycin formulation of choice.

Vancomycin is the essential antibiotic that is on the WHO’s list of essential medicines, which is one of the safe and effective medicines required in the health system of the country. With experience in Injectable Drug Subcutaneous Subq Formulation, Latitude has created the Intra-V and has got it recognized by USPTO as well.

About Latitude Pharmaceuticals Inc.:
Latitude Pharma employs a wide range of technologies and techniques many of which are proprietary and unique.

For more information, please visit http://latitudepharma.com/

Media Contact:
Latitude Pharmaceuticals Inc.
Tel: 858-546-0924
Email: [email protected]